Issue №3-85, 2018

Objective Control of Hearing Ability of Children with Cystic Fibrosis Who Have not Complained of Hearing Loss

View article (Download PDF file)



Download XML file

1 Ishanova J.S., 1 Zonenko O.G., 1 Dyakonova I.N., 1 Shumilov P.V., 1 Rahmanova I.V.

1 Pirogov Russian National Research Medical University, Moscow, Russia


ABSTRACT

The study shows the objective data collected during research on hearing ability among 45 children with cystic fibrosiswho have been treated with ototoxic antibiotics at least twice and who have not complained of hearing loss. Due to atympanography testing it has been discovered a middle ear pathology among 13,3% of the cases and an evoked otoacousticemission helped to identify a hearing disorder in 43,6% of the cases. The said disorder involves first and foremost the outerhair cells function, responsible for the 4 kHz frequency. In the cases of failed testing the hearing dysfuntion occurs on the0,5 2 4 6 8 kHz frequencies. This obtained data indicates the necessity to conduct an objective hearing monitoring for thepatients with cystic fibrosis, who have been treated with ototoxic antibiotics.


KEYWORDS: cystic fibrosis, pseudomonas aureginosa, aminoglycosides, ototoxicity, hearing loss, tympanometry, otoacoustic emissions



References:

  1. Kapranov N.I., Kashirskaya N.Yu. «Mukoviscidoz», Medpraktika-M, Moskva, 2014.
  2. Kondrateva E.I., Kashirskaya N.Yu., Kapranov N.I. «Mukoviscidoz: opredelenie, diagnosticheskie kriterii, terapiya»//Nacionalnyj koncensus Moskva 2016
  3. Kondrateva E.I., Krasovskij S.A., Voronkova A.Yu,,Amelina E.L., Chernyak A.V., Kashirskaya N.Yu. // Registr bolnyh mukoviscidozom v Rossijskoj federacii. 2015 god. «Medpraktika-M», 2016.
  4. Krasovskij S.A., Amelina E.L., Kondrateva E.I.,i dr. «Medikamentoznoe lechenie mukoviscidoza v Rossii: analiz dannyh nacionalnogo Registra (2014)» // «Pulmonologiya», Tom 26, № 5 (2016) s. 539-555.
  5. Al-Malky G1, Suri R, Dawson SJ, Sirimanna T, Kemp D. Aminoglycoside antibiotics cochleotoxicity in paediatric cystic fibrosis (CF) patients: A study using extended high-frequency audiometry and distortion product otoacoustic emissions. Int J Audiol. 2011;50(2):112-22.
  6. Farzal Z1,2, Kou YF1, St John R3, Shah GB1,3, Mitchell RB1,3. The role of routine hearing screening in children with cystic fibrosis on aminoglycosides: A systematic review. Laryngoscope. 2016;126(1):228-35
  7. Garinis AC, Keefe DH, Hunter LL, Fitzpatrick DF, Putterman DB, McMillan GP, Gold JA, Feeney MP. Chirp-Evoked Otoacoustic Emissions and Middle Ear Absorbance for Monitoring Ototoxicity in Cystic Fibrosis Patients. Ear Hear. 2017 Jul 13. doi: 10.1097/AUD
  8. Prayle A1, Smyth AR. Aminoglycoside use in cystic fibrosis: therapeutic strategies and toxicity. Curr Opin Pulm Med. 2010 Nov;16(6):604-10.
  9. Tarshish Y, Huang L, Jackson FI, Edwards J, Fligor B, Wilkins A, Uluer A, Sawicki G, Kenna M. Risk Factors for Hearing Loss in Patients with Cystic Fibrosis. J Am Acad Audiol. 2016;27(1):6-12.



Creative Commons License
The content is available under the Creative Commons Attribution 4.0 License.

©

Эта статья открытого доступа по лицензии CC BY 4.0. Издательство: ФГБУ «НМИЦ РК» Минздрава России.
This is an open article under the CC BY 4.0 license. Published by the National Medical Research Center for Rehabilitation and Balneology.